Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.
Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schär S, Milan L, Pirosa MC, Esposito F, Ruberto T, Giovanella L, Hayoz S, Mamot C, Dirnhofer S, Zucca E, Ceriani L. Genta S, et al. Among authors: hayoz s. Cancers (Basel). 2022 Feb 17;14(4):1018. doi: 10.3390/cancers14041018. Cancers (Basel). 2022. PMID: 35205765 Free PMC article.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Zucca E, et al. Among authors: hayoz s. Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17. Blood. 2019. PMID: 31101627 Free article. Clinical Trial.
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy.
Menter T, Tzankov A, Zucca E, Kimby E, Hultdin M, Sundström C, Beiske K, Cogliatti S, Banz Y, Cathomas G, Karjalainen-Lindsberg ML, Grobholz R, Mazzucchelli L, Sander B, Hawle H, Hayoz S, Dirnhofer S. Menter T, et al. Among authors: hayoz s. Br J Haematol. 2020 May;189(4):707-717. doi: 10.1111/bjh.16414. Epub 2020 Feb 3. Br J Haematol. 2020. PMID: 32012230 Free article.
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, Stathis A, Bruno A, Moccia AA, Giovanella L, Hayoz S, Schär S, Dirnhofer S, Rambaldi A, Martinelli G, Mamot C, Zucca E. Ceriani L, et al. Among authors: hayoz s. Blood Adv. 2020 Mar 24;4(6):1082-1092. doi: 10.1182/bloodadvances.2019001201. Blood Adv. 2020. PMID: 32196557 Free PMC article.
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA, Schär S, Hayoz S, Pirosa MC, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: hayoz s. Br J Haematol. 2021 Mar;192(6):1031-1034. doi: 10.1111/bjh.17045. Epub 2020 Aug 17. Br J Haematol. 2021. PMID: 32805081 Free article. Clinical Trial.
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L. Zucca E, et al. Among authors: hayoz s. Hematol Oncol. 2020 Dec;38(5):715-725. doi: 10.1002/hon.2805. Epub 2020 Oct 4. Hematol Oncol. 2020. PMID: 32947651
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: hayoz s. Blood Adv. 2020 Dec 8;4(23):5951-5957. doi: 10.1182/bloodadvances.2020002858. Blood Adv. 2020. PMID: 33275769 Free PMC article. Clinical Trial.
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E. Ceriani L, et al. Among authors: hayoz s. Hematol Oncol. 2022 Feb;40(1):11-21. doi: 10.1002/hon.2935. Epub 2021 Oct 29. Hematol Oncol. 2022. PMID: 34714558
Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
Beck M, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Hayoz S, Schär C, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Aebersold DM, Ghadjar P, Pra AD. Beck M, et al. Among authors: hayoz s. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):80-91. doi: 10.1016/j.ijrobp.2021.12.174. Epub 2022 Jan 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 34990777 Free article.
104 results